Anna Rychter, Joanna Miniszewska, Joanna Góra-Tybor
{"title":"Personality traits favourable for non-adherence to treatment in patients with chronic myeloid leukaemia: role of type A and D personality.","authors":"Anna Rychter, Joanna Miniszewska, Joanna Góra-Tybor","doi":"10.1186/s13030-023-00261-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The introduction of BCR-ABL tyrosine kinase inhibitors (TKIs) to chronic myeloid leukemia (CML) therapy has revolutionized the treatment of this disease. Although regular TKI intake is a prerequisite for successful therapy, it has been shown that a significant proportion of patients are non-compliant. Recently there is growing evidence that personality traits may influenced the tendency for non-adherence to treatment in patients with chronic diseases. As far as we know, such a relationship in patients with CML has not been examined, yet. The aim of our study was to determine if personality traits favor non-adherence to treatment recommendations. We investigated the relationship between five-factor model personality factors (conscientiousness, neuroticism, agreeableness, extraversion, and openness) and medication non-adherence. We also checked if the patients with type A and type D personality, were at higher risk of poor medication adherence.</p><p><strong>Methods: </strong>The following tools were used: self-constructed survey, the NEO-Five Factor Inventory, the Framingham Type A Scale, the D-Scale 14. The study included 140 CML patients treated with imatinib, dasatinib, or nilotinib.</p><p><strong>Results: </strong>39% of patients reported skipping at least one dose of medication in the month prior to follow-up visit. 51% admitted to skipping such doses from the start of their treatment to the time at which our assessment was performed. We did not find any relationship between the mean values of the analyzed factors of the Big Five (neuroticism, extraversion, openness, agreeableness, conscientiousness) and adherence. However, our analysis revealed that CML patients who admitted to missing doses of drugs during the entire course of treatment demonstrated greater intensity of type A personality traits (p = 0.020). Regarding both factors of type D personality, it was revealed that higher level of negative affectivity significantly decreased the adherence (p = 0.020).</p><p><strong>Conclusion: </strong>The results of our study indicate that screening for type D and A personalities may help to identify patients who are at higher risk of poor medication adherence.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2023-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854114/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13030-023-00261-w","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The introduction of BCR-ABL tyrosine kinase inhibitors (TKIs) to chronic myeloid leukemia (CML) therapy has revolutionized the treatment of this disease. Although regular TKI intake is a prerequisite for successful therapy, it has been shown that a significant proportion of patients are non-compliant. Recently there is growing evidence that personality traits may influenced the tendency for non-adherence to treatment in patients with chronic diseases. As far as we know, such a relationship in patients with CML has not been examined, yet. The aim of our study was to determine if personality traits favor non-adherence to treatment recommendations. We investigated the relationship between five-factor model personality factors (conscientiousness, neuroticism, agreeableness, extraversion, and openness) and medication non-adherence. We also checked if the patients with type A and type D personality, were at higher risk of poor medication adherence.
Methods: The following tools were used: self-constructed survey, the NEO-Five Factor Inventory, the Framingham Type A Scale, the D-Scale 14. The study included 140 CML patients treated with imatinib, dasatinib, or nilotinib.
Results: 39% of patients reported skipping at least one dose of medication in the month prior to follow-up visit. 51% admitted to skipping such doses from the start of their treatment to the time at which our assessment was performed. We did not find any relationship between the mean values of the analyzed factors of the Big Five (neuroticism, extraversion, openness, agreeableness, conscientiousness) and adherence. However, our analysis revealed that CML patients who admitted to missing doses of drugs during the entire course of treatment demonstrated greater intensity of type A personality traits (p = 0.020). Regarding both factors of type D personality, it was revealed that higher level of negative affectivity significantly decreased the adherence (p = 0.020).
Conclusion: The results of our study indicate that screening for type D and A personalities may help to identify patients who are at higher risk of poor medication adherence.
背景:在慢性髓性白血病(CML)治疗中引入BCR-ABL酪氨酸激酶抑制剂(TKIs)后,该病的治疗发生了革命性的变化。虽然定期服用 TKI 是成功治疗的先决条件,但事实证明,相当一部分患者并不依从。最近有越来越多的证据表明,人格特征可能会影响慢性病患者不坚持治疗的倾向。据我们所知,这种关系在慢性骨髓性白血病患者中尚未得到研究。我们的研究旨在确定人格特质是否有利于不遵从治疗建议。我们研究了五因素模型人格因素(自觉性、神经质、宜人性、外向性和开放性)与不遵医嘱用药之间的关系。我们还检测了 A 型和 D 型人格患者是否有更高的服药依从性风险:使用了以下工具:自建调查表、NEO-五因子量表、弗拉明汉 A 型量表、D 型量表 14。研究对象包括140名接受伊马替尼、达沙替尼或尼洛替尼治疗的CML患者:39%的患者表示在随访前一个月至少漏服了一次药物。51%的患者承认从开始接受治疗到我们进行评估期间曾漏服药物。我们没有发现五大因素(神经质、外向性、开放性、宜人性、自觉性)的平均值与依从性之间有任何关系。然而,我们的分析表明,承认在整个治疗过程中漏服药物的 CML 患者表现出更强的 A 型人格特质(p = 0.020)。关于 D 型人格的两个因素,结果显示,较高程度的消极情绪会显著降低依从性(p = 0.020):我们的研究结果表明,对 D 型和 A 型人格进行筛查可能有助于识别服药依从性较差的高危患者。